Showing results (251-260 of 262) with videos related to
Sort By:
Pageof 27
Respiratory Medicine and Research|May 23, 2021
Daily multidisciplinary COVID-19 meeting: Experiences from a French university hospitalC Rolland-Debord, A Canellas, P Choinier, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†G R Blumenschein, E F Smit, D Planchard, et al.The European Respiratory Journal|July 9, 2011
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendationsT Berghmans, F Pasleau, M Paesmans, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutationsJ Mazieres, C Cropet, L Montané, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT networkM Beau-Faller, N Prim, A-M Ruppert, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trialG Zalcman, A Madroszyk, E Guenzi, et al.Clinical Lung Cancer|August 12, 2025
AFSOS-SFRO Guidelines on Radiation-Induced Lung InjuryO Cravereau, V Bourbonne, L Vaugier, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyF de Marinis, T M Kim, L Bonanno, et al.Revue Des Maladies Respiratoires|June 25, 2022
[French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]V Cottin, P Bonniaud, J Cadranel, et al.Revue Des Maladies Respiratoires|March 19, 2022
[French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]V Cottin, P Bonniaud, J Cadranel, et al.Pageof 27